Clinical trial NCT01460888: Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
Official title: Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Carcinoma of the Oesophagus
Lead sponsor: The Christie NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Cancer Research UK
name: AstraZeneca
First posted: 2011-10-27
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for platinum containing chemotherapy.


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the oesophagus including Siewert type 1 or 2 tumours with ≤2cm gastric mucosal extension
2. Unsuitable for radical chemoradiation therapy but suitable for radiotherapy
3. Total length of tumour and involved lymph nodes ≤10cm
4. No oesophageal stent in situ
5. No previous chemotherapy or radiotherapy for oesophagus cancer
6. Disease which can be encompassed within a radical radiotherapy treatment volume
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see ECOG criteria appendix 1)
8. Provision of fully informed consent, signed, written and dated, prior to any study specific procedures.
9. \> 18 years of age.
10. Adequate organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    * Haemoglobin ≥ 10.0 g/dL
    * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    * White blood cells (WBC) \> 3 x 109/L
    * Platelet count ≥ 100 x 109/L
    * No dysplastic features on peripheral blood smear
    * Total bilirubin ≤ 1.5 x institutional upper limit of normal
    * Aspartate aminotransferase (AST(SGOT)/Alanine transaminase (ALT)SGPT) ≤ 2.5 x institutional upper limit of normal
    * Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
11. Adequate lung function: no history of interstitial lung disease and FEV1 \> 1litre and \>30% predicted.
12. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. Postmenopausal is defined as:

    * Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
    * Luteinizing hormone(LH) and Follicle-stimulating hormone (FSH) levels in the post menopausal range for women under 50,
    * radiation-induced oophorectomy with last menses \>1 year ago,
    * chemotherapy-induced menopause with \>1 year interval since last menses,
    * surgical sterilisation (bilateral oophorectomy or hysterectomy).
13. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
14. Fit to receive all study treatments
15. Swallowing sufficiently good to tolerate oral medication
16. Life expectancy ≥ 4 months.

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
2. Previous enrolment in the present study
3. Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used)
4. Any previous treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, including olaparib.
5. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years.
6. Patients receiving the following classes of inhibitors of cytochrome P450 3A4 (CYP3A4)

   * Azole antifungals
   * Macrolide antibiotics
   * Protease inhibitors
7. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
8. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, or any psychiatric disorder that prohibits obtaining informed consent.
9. Patients with a history of interstitial lung disease, inflammatory lung conditions, or severe chronic obstructive pulmonary disease (COPD) (FEV1\<1litre or \< 30% predicted). Patients with pneumonia within the previous 3 months.
10. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
11. Patients with oesophageal stent in-situ
12. Patients with myelodysplastic syndrome/acute myeloid leukaemia
13. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
14. Patients with known active hepatic disease (i.e., Hepatitis B or C).
15. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
16. Patients with uncontrolled seizures.
17. Concurrent uncontrolled medical illness, or other previous or current malignant disease likely to interfere with protocol treatments / comparisons
18. Age \< 18
19. Any pregnant, lactating women or potentially childbearing patients not using adequate contraception (see section 3.4 for details of required contraception).
20. Previous chemotherapy or radiotherapy for oesophageal cancer
21. Metastatic disease apart from local lymph node disease which can be reasonably encompassed within the radiotherapy volume (total length of tumour and lymph node disease should be \<10cm)
22. ECOG performance status \>2

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer
timeFrame: 3 months post treatment
Secondary outcomes:
measure: Overall toxicity profile of treatment (NCRI Common Toxicity Criteria for Adverse Effects V3)
timeFrame: Assessed at all study visits, up to 3 years post treatment.
measure: Olaparib compliance
timeFrame: At completion of olaparib treatment (end of week 5)
measure: Radiotherapy (RT) compliance
timeFrame: At completion of RT treatment (end of week 5)
measure: Local and overall treatment failure rate
timeFrame: 3 months
measure: Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.
timeFrame: Up to 3 months post treatment
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Southampton
country: United Kingdom
facility: Southampton General Hospital
Study officials:
affiliation: University Hospital Southampton NHS Foundation Trust
name: Andrew Jackson, Dr
role: PRINCIPAL_INVESTIGATOR
References: